KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Revenue (2016 - 2025)

Historic Revenue for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $4.7 billion.

  • Teva Pharmaceutical Industries' Revenue rose 1139.75% to $4.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $17.3 billion, marking a year-over-year increase of 431.58%. This contributed to the annual value of $17.3 billion for FY2025, which is 431.58% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Revenue stood at $4.7 billion for Q4 2025, which was up 1139.75% from $4.5 billion recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Revenue ranged from a high of $4.7 billion in Q4 2025 and a low of $3.6 billion during Q3 2022
  • Moreover, its 5-year median value for Revenue was $3.9 billion (2021), whereas its average is $4.0 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Revenue crashed by 860.68% in 2021, and later surged by 1475.28% in 2023.
  • Teva Pharmaceutical Industries' Revenue (Quarter) stood at $4.1 billion in 2021, then fell by 5.27% to $3.9 billion in 2022, then grew by 14.75% to $4.5 billion in 2023, then decreased by 5.12% to $4.2 billion in 2024, then increased by 11.4% to $4.7 billion in 2025.
  • Its Revenue was $4.7 billion in Q4 2025, compared to $4.5 billion in Q3 2025 and $4.2 billion in Q2 2025.